rs4149338 — ABCA1 ABCA1 3'UTR Stroke-Associated Variant

ABCA1 3'UTR Variant — Cholesterol Efflux Capacity and Cerebrovascular Risk

Cholesterol doesn't simply move through the bloodstream on its own. In arterial walls and the brain, cells loaded with excess cholesterol depend on a specialized transporter — ABCA1 (ATP-binding cassette transporter A1)¹¹ ABCA1 (ATP-binding cassette transporter A1)
A membrane-spanning protein that pumps cholesterol and phospholipids from cells onto lipid-poor apolipoprotein A-I (ApoA-I), initiating the formation of nascent HDL particles and the reverse cholesterol transport pathway that carries cholesterol back to the liver for excretion — to offload that cholesterol. rs4149338 sits in the 3' untranslated region of the ABCA1 gene, a regulatory zone that influences how efficiently the mRNA is translated and stabilized. The G allele at this position has been linked to impaired cholesterol efflux capacity and, in a Chinese Han population study, to a roughly 2.5-fold enrichment of the homozygous GG genotype among ischemic stroke patients compared to healthy controls.

The Mechanism

The variant is located at position 104,783,622 on chromosome 9 (GRCh38), in the 3' untranslated region of the ABCA1 transcript (NM_005502.4: c.*693C>T, where the plus-strand G corresponds to C in the minus-strand transcript, and plus-strand A corresponds to T). ABCA1 is on the minus strand; the 3'UTR is a well-recognized site for post-transcriptional regulation, where microRNAs, RNA-binding proteins, and regulatory sequences can alter mRNA half-life and translational efficiency without changing the protein sequence.

When ABCA1 expression is reduced — whether through coding mutations (as in Tangier disease), regulatory variants, or 3'UTR changes — the ability of macrophages, hepatocytes, and brain cells to off-load intracellular cholesterol onto ApoA-I is compromised. In the vasculature, this impairs macrophage reverse cholesterol transport and promotes foam cell formation in atherosclerotic plaques. In cerebral vessels, ABCA1-mediated efflux is critical for maintaining endothelial lipid homeostasis and neurovascular stability. The GG genotype at rs4149338 may reduce ABCA1 function through 3'UTR-mediated destabilization of the mRNA or impaired translation; however, the precise molecular mechanism has not yet been established experimentally for this specific variant.

The Evidence

The primary association evidence comes from a Chinese Han case-control study by Yang et al. 2022²² Chinese Han case-control study by Yang et al. 2022
Yang S et al. Genetic variations in ABCA1/G1 associated with plasma lipid levels and risk of ischemic stroke. Gene. 2022;823:146343, which enrolled 249 ischemic stroke (IS) patients and 226 healthy controls. The GG genotype of rs4149338 was present in 11.4% of IS patients but only 4.6% of controls (p=0.037). Importantly, GG carriers had lower total cholesterol than AA carriers, consistent with altered ABCA1-mediated cholesterol metabolism. Note that in East Asian populations, the G allele is the minor allele (~23% frequency), making GG genotype rare (~5%) — the enrichment in stroke patients therefore represents a meaningful shift from baseline expectation.

Haplotype evidence from Lu et al. 2015³³ Lu et al. 2015
Lu Y et al. Association of ATP-binding cassette transporter A1 gene polymorphisms with plasma lipid variability and coronary heart disease risk. Int J Clin Exp Pathol. 2015;8(10):13441-9, in 754 CHD patients and 760 Chinese Han controls, placed rs4149338 as part of a GCC haplotype (with rs363717 and rs4149339) associated with decreased CHD risk (OR=0.8, p=0.027). The C allele of rs4149338 contributes to this haplotype and is rare; the haplotype-level finding is consistent with G being the unfavorable allele, though the SNP-level signal at rs4149338 specifically may be driven by haplotype context. Rs4149338 also showed a statistically significant interaction with elevated triglyceride levels on CHD risk (p=0.020), suggesting the variant modulates how plasma lipid environment translates into cardiovascular events.

Broader ABCA1 variant studies in Caucasian and Hungarian populations found reduced frequencies of ABCA1 polymorphisms R219K and V771M in stroke and CHD patients versus controls, particularly in younger patients. These findings, taken together, support a role for ABCA1 genetic variation in cerebrovascular risk — though the specific SNP, direction of effect, and population-specificity vary across studies.

Evidence level is emerging: the rs4149338-stroke association rests on a single case-control study (n=475 total) in a Chinese Han population, with no large independent replication. The variant itself has not been functionally characterized in vitro. This is a suggestive but preliminary finding requiring confirmation in larger, multiethnic cohorts.

Practical Actions

For GG homozygotes — particularly relevant for individuals of non-East-Asian ancestry, where GG genotype is more common (~49% globally versus ~5% in East Asians) — the key actionable implication is supporting optimal ABCA1-mediated cholesterol efflux capacity. Omega-3 fatty acids (EPA and DHA) have been shown in animal models to upregulate ABCA1 expression via SIRT1 activation, enhancing macrophage cholesterol efflux and reducing intracranial atherosclerotic stenosis. Monitoring HDL-C and total cholesterol provides indirect evidence of cholesterol efflux pathway function; chronically low HDL with elevated total cholesterol in a GG carrier warrants active lipid management.

Interactions

rs4149338 lies in the same haplotype block as rs4149339 and rs363717 (two additional ABCA1 3'UTR and nearby variants). The GCC haplotype analysis in Lu et al. 2015 treated these three SNPs as a unit, making individual SNP contributions difficult to disentangle. Rs2230806 (ABCA1 R219K, a well-studied coding variant) is the most clinically characterized ABCA1 polymorphism; carriers of the R219K variant who also carry the GG genotype at rs4149338 might have compounded impairment of cholesterol efflux, though no study has directly tested this combination. ABCG1 variants (including those co-analyzed in Yang et al. 2022) interact with ABCA1 in the reverse cholesterol transport pathway and may modify the stroke risk conveyed by rs4149338.